XERIS BIOPHARMA HOLDINGS, INC. Stock-Based Compensation
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Stock-Based Compensation of $15.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $11.07M, a 120.97% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $4.14M, a 6.82% decline year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $5.27M, a 46.65% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $7.64M, a 12.93% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $22.37M, a 21.80% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $18.36M, a 71.36% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $10.72M, a 11.88% decline from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $12.16M, a 6.84% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $15.21M 10-Q · filed 2026-08-06 | $20.48M derived: sum of 3 quarters · filed 2026-08-06 | $28.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.14M 10-Q · filed 2026-05-07 | $9.41M derived: sum of 2 quarters · filed 2026-05-07 | $17.05M derived: sum of 3 quarters · filed 2026-05-07 | $22.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $5.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $12.91M derived: sum of 2 quarters · filed 2026-03-02 | $17.92M derived: sum of 3 quarters · filed 2026-08-06 | $22.37M 10-K · filed 2026-03-02 |
| 2025-09-30 | $7.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $12.65M derived: sum of 2 quarters · filed 2026-08-06 | $17.09M 10-Q · filed 2025-11-06 | $20.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $5.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $9.45M 10-Q · filed 2026-08-06 | $13.05M derived: sum of 3 quarters · filed 2026-08-06 | $19.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $4.44M 10-Q · filed 2026-05-07 | $8.04M derived: sum of 2 quarters · filed 2026-05-07 | $14.81M derived: sum of 3 quarters · filed 2026-05-07 | $19.04M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $10.36M derived: sum of 2 quarters · filed 2026-03-02 | $14.60M derived: sum of 3 quarters · filed 2026-03-02 | $18.36M 10-K · filed 2026-03-02 |
| 2024-09-30 | $6.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $11.00M derived: sum of 2 quarters · filed 2025-11-06 | $14.77M 10-Q · filed 2025-11-06 | $17.54M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $4.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $8.00M 10-Q · filed 2025-08-07 | $10.77M derived: sum of 3 quarters · filed 2026-03-02 | $13.22M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $3.77M 10-Q · filed 2025-05-08 | $6.53M derived: sum of 2 quarters · filed 2026-03-02 | $8.99M derived: sum of 3 quarters · filed 2026-03-02 | $11.92M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $5.22M derived: sum of 2 quarters · filed 2026-03-02 | $8.15M derived: sum of 3 quarters · filed 2026-03-02 | $10.72M 10-K · filed 2026-03-02 |
| 2023-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $5.38M derived: sum of 2 quarters · filed 2024-11-08 | $7.95M 10-Q · filed 2024-11-08 | $10.71M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $2.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $5.49M 10-Q · filed 2024-08-08 | $8.26M derived: sum of 3 quarters · filed 2025-03-06 | $11.20M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $2.56M 10-Q · filed 2024-05-09 | $5.33M derived: sum of 2 quarters · filed 2025-03-06 | $8.27M derived: sum of 3 quarters · filed 2025-03-06 | $11.42M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $2.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $5.71M derived: sum of 2 quarters · filed 2025-03-06 | $8.86M derived: sum of 3 quarters · filed 2025-03-06 | $12.16M 10-K · filed 2025-03-06 |
| 2022-09-30 | $2.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $6.09M derived: sum of 2 quarters · filed 2023-11-09 | $9.39M 10-Q · filed 2023-11-09 | $12.14M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $3.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $6.45M 10-Q · filed 2023-08-08 | $9.20M derived: sum of 3 quarters · filed 2024-03-06 | $12.86M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $3.30M 10-Q · filed 2023-05-09 | $6.04M derived: sum of 2 quarters · filed 2024-03-06 | $9.71M derived: sum of 3 quarters · filed 2024-03-06 | $12.22M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $6.41M derived: sum of 2 quarters · filed 2024-03-06 | $8.92M derived: sum of 3 quarters · filed 2024-03-06 | $11.38M 10-K · filed 2024-03-06 |
| 2021-09-30 | $3.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $6.18M derived: sum of 2 quarters · filed 2022-11-09 | $8.64M 10-Q · filed 2022-11-09 | $10.78M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $4.97M 10-Q · filed 2022-08-10 | $7.11M derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $2.46M 10-Q · filed 2022-05-11 | $4.60M derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $8.27M 10-K · filed 2022-03-11 | ||
| 2020-09-30 | $6.13M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |